fda approval ghk cu injection GHK-CU FDA scientists flag concerns with

(2020) demonstrated that GHK-Cu protected against bleomycin-induced pulmonary fibrosis in mice via anti-inflammatory mechanisms, reducing fibrotic tissue accumulation and preserving lung function

The 503A designation is critical

Patients often report: Reduction in bloating and abdominal pain within 2-3 weeks Improved bowel movement regularity by week 4-6 Enhanced tolerance to previously problematic foods by week 8-12 Reduced systemic inflammation (measured by CRP, ESR) after 12 weeks of consistent use BPC-157 for Musculoskeletal Healing: Tendons, Ligaments, and Joints For musculoskeletal applications, BPC-157 is typically administered via subcutaneous injection near the injury site

Science 336 , 11501153 (2012)

Variations in the GHRL gene which produces ghrelin influence hunger regulation